[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncologic-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncologic-disorders":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,73,101,123,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645190","immersive-virtual-reality-applied-to-therapeutic-physical-exercise-in-cellular-therapy-100645190",false,"NCT07679958","Immersive Virtual Reality Applied to Therapeutic Physical Exercise in Cellular Therapy","RVI-ET","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Signed informed consent.\n* Patients eligible for CT scan at the Alvaro Cunqueiro Hospital.\n* Patients capable of performing therapeutic exercise independently, based on an objective initial functional assessment.\n* The clinical investigator, in their professional judgment, determines that the patient can adhere to all study requirements.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Any medical condition or mental illness that could interfere with understanding HIP and CI.\n* Patients participating in another clinical trial.\n* Balance disorders that increase the risk of falls.\n* Severe visual and\u002For auditory impairments that prevent participation in the session.\n* History of vertigo, seizures, or epileptic fits.","ALL","18 Years",{"count":19,"type":20},144,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cell therapy (CT), including hematopoietic stem cell transplantation (HSCT) and advanced CAR T-cell therapies, is used for the treatment of oncohematological and other diseases. HSCT is associated with treatment-related toxicities, including fatigue, muscle weakness, and reduced functional capacity due to intensive conditioning chemotherapy, immunosuppressive treatments, corticosteroids, and complications such as infections or graft-versus-host disease. Emotional symptoms, including anxiety, depression, fear, and frustration, also affect patients' recovery and ability to regain functional independence. Evidence indicates that exercise interventions improve emotional well-being, fatigue, quality of life, physical function, cardiovascular fitness, and muscle mass in patients with hematological malignancies and HSCT recipients.\n\nVirtual reality (VR) has emerged as an innovative tool in rehabilitation, supporting patient motivation, exercise guidance, and monitoring. Immersive virtual reality (IVR), through head-mounted displays and multisensory environments, enhances the sense of presence and engagement. Studies suggest that IVR-based exercise programs are feasible, improving functional abilities, quality of life, satisfaction, and adherence.\n\nSince 2017, a Therapeutic Exercise program for patients admitted for HSCT has been implemented at Álvaro Cunqueiro Hospital (Vigo) through collaboration between the Physiotherapy Unit and the Hematology Department. Before admission, patients undergo a physical assessment, receive an individualized exercise plan, education, and a therapeutic exercise guide. Based on clinical experience, the team hypothesizes that integrating IVR into therapeutic exercise may improve motivation, adherence, and emotional well-being during hospitalization.",[26,27,28,29,30],"Hematologic Diseases","Hematopoietic Stem Cell Transplantation","Cellular Therapy","Quality of Life","Oncologic Disorders",[32,33,34],"Therapeutic Exercise","Immersive virtual reality","Cellular therapy","NOT_YET_RECRUITING","2026-06-25",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":20},"2026-07-24",{"date":43,"type":20},"2029-06-01",{"name":45,"class":46},"Fundacin Biomedica Galicia Sur","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100642172","physical-exercise-during-the-cancer-care-pathway-100642172","NCT07652502","Physical Exercise During the Cancer Care Pathway","ECOLE","Inclusion Criteria:\n\n* Age ≥18 years\n* Oncological diagnosis\n* Ability to understand the language of the respective country of origin\n* Electronic informed consent\n\nExclusion Criteria:\n\n\\- Failure to accept the informed consent",{"count":56,"type":20},370,"OBSERVATIONAL","Background: Physical exercise is proven safe and effective in improving quality of life and reducing treatment-related side effects in oncology. However, patient adherence to international guidelines remains suboptimal. Investigating the knowledge, attitudes, and practices (KAP) regarding physical activity is crucial to identifying unmet educational needs and barriers.\n\nObjective: This multicenter, cross-sectional observational study (ECOLE project) aims to assess KAP levels concerning exercise among cancer patients and explore the correlations between KAP scores and sociodemographic or clinical variables.\n\nMethods: Over a 6-month period, an anonymous online survey (Microsoft Forms) will be administered to adult cancer patients (≥18 years old) at any disease or treatment stage. A minimum sample size of 370 participants is targeted. Statistical analyses will include Descriptive Statistics, Exploratory and Confirmatory Factor Analyses to validate KAP scales, and Multivariable Logistic Regression to identify predictors of adherence (≥150 minutes\u002Fweek) and perceived barriers or facilitators.\n\nExpected Results: The study will provide a comprehensive overview of physical activity perceptions and behaviors in oncology. These insights will support the design of targeted educational interventions and structured exercise programs, contributing to the development of a novel \"Exercise Oncology Specialist\" within supportive care teams.",[60,61,62,30],"Cancer, Treatment-Related","Cancer","Oncology","2026-06-23",{"date":65,"type":39},"2026-06-26",{"date":67,"type":20},"2026-06-15",{"date":69,"type":20},"2027-10-30",{"name":71,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100632909","llm-generated-plain-language-patient-synopses-to-improve-comprehension-in-hematology-and-oncology-oncopal-100632909","NCT07519811","LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)","Prospective Randomized Controlled Trial to Evaluate Locally Implemented Large Language Models (LLMs) for Simplifying Patient Communication in Hematology and Oncology","oncOPAL","Inclusion Criteria:\n\n* Age 18 years or older\n* Inpatient of the Department of Medicine III (Hematology\u002FOncology) at TUM University Hospital (Klinikum rechts der Isar), Munich, Germany\n* Receipt of a discharge letter including the sections Current Status, Medical History, Epicrisis, and Further Management as part of routine clinical care\n* Capacity to provide informed consent\n* Written informed consent following the consent procedure\n\nExclusion Criteria:\n\n* Cognitive impairment precluding independent assessment of comprehension (e.g., dementia, severe encephalopathy)\n* Participation in another study with potential influence on the study endpoints\n* Lack of capacity to provide informed consent\n* Refusal to participate in the study",{"count":82,"type":20},150,[23],"This study tests whether patients with blood cancer or other cancers better understand their medical information when it is rewritten in plain language by an artificial intelligence (AI) system.\n\nWhen patients are discharged from the hospital, they receive a medical letter summarizing their diagnosis, treatment, and next steps. These letters are often written in technical language that is difficult for patients to understand. In this study, an AI language model running on the hospital's own secure servers rewrites parts of this letter into simpler language. A physician checks the simplified version before the patient receives it.\n\nPatients are randomly assigned to one of two groups. One group receives both the standard medical letter and the AI-simplified version. The other group receives the standard letter only. A separate group of patients who do not speak German well will receive a simplified and translated version.\n\nAfter reading their letter, all participants fill out a short questionnaire about how well they understood the information. The study takes place at TUM University Hospital (Klinikum rechts der Isar) in Munich, Germany.",[86,30],"Hematologic Neoplasms",[88,89,90],"Patient-Provider Communication","Patient Health Literacy","Large Language Model","RECRUITING","2026-04-13",{"date":94,"type":39},"2026-04-16",{"date":96,"type":39},"2026-04-01",{"date":98,"type":20},"2027-04-01",{"name":100,"class":46},"Technical University of Munich",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":47},"100556297","advanced-imaging-holistic-omics-biobank-100556297","NCT06523270","Advanced Imaging Holistic Omics Biobank","Inclusion Criteria:\n\n* Adult subjects (\\>18 y.o.) submitted to Computed Tomography (CT) using Photon Counting CT scanner (Neaotom Alpha, Siemens) and Magnetic Resonance (MRI) exams acquired with 3T scanner (MR 7700, Philips) for examination required for clinical practice or for clinical trials at the IRCCS San Raffaele Hospital who signe an Informed Consent authorizing data collection.\n\nExclusion Criteria:\n\n* Absent informed consent signed",{"count":108,"type":20},50000,"Imaging methods today represent the pillar of prevention, diagnosis, patients monitoring and treatment. Improvement in technology led the development of increasingly high-performance scanners whose potential has not yet been fully explored. In particular, recently introduced photon counting CT scanner and new high filed MRI offers a lake of latent information derived from the images (e.g. spectral data from CT) of potentially great interest and potentially able to provide new insight but that are currently mostly unexplored .These features are also called \"opportunist features\" because they are in each exam and can be freely derived from images without changing the study protocol used for clinical practice examination but extracted a posteriori from the images representing a precious source of deep characterization of the patients, equally or even more than a genomic analysis, with possible high relevance in the field of screening and prevention, being able to contribute to defining signatures indicating a particular risk of remotely developing a specific pathological condition. The prospective collection of clinical and imaging data from subjects undergoing diagnostic tests with advanced technology has the potential to increase knowledge of the pathophysiological mechanisms of different pathological conditions, to explore and validate the diagnostic-predictive value of opportunistic features not currently used in practice clinical, to increase the diagnostic and prognostic accuracy of CT and MRI examinations and to provide a unique pool for scientific research. Previous relevant experience was conducted in the United Kingdom (UK biobank) where data from over 500,000 patients have been collected in the last 10 years, providing an enormous pool for spontaneous and funded scientific research. This project (UK biobank), although of enormous scientific value, is currently obsolete in terms of the imaging technology used.",[30,111,112,113],"Neurologic Disorder","Pulmonary Disease","Cardiovascular Diseases","2026-01-14",{"date":116,"type":39},"2026-01-15",{"date":118,"type":39},"2024-09-15",{"date":120,"type":20},"2034-09-15",{"name":122,"class":46},"IRCCS San Raffaele",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100576216","phase-2-multicenter-validation-trial-of-18falf-fapi-74-for-pet-imaging-of-cancer-associated-fibroblasts-through-fibroblast-activation-protein-inhibitors-fapi-in-different-tumor-types-100576216","NCT06782412","Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types","FAPIDO","Inclusion Criteria OGA:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Age 18 or older.\n3. New histologic or cytologic proven diagnosis of oesophagogastric adenocarcinoma.\n4. Patient underwent a \\[18F\\]FDG PET\u002FCT.\n5. TNM classification: cT1-4N0-3M0\n\nInclusion Criteria PDAC:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Age 18 or older.\n3. New histologic or cytologic proven diagnosis of pancreatic ductal adenocarcinoma.\n4. Patient underwent a \\[18F\\]FDG PET\u002FCT or conventional staging with CT or MRI.\n5. TNM classification: cT1-4N0-2M0-1, with the exception of upfront resectable patients.\n\nInclusion Criteria Clinically challenging cohort:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Age 18 or older.\n3. Histologic or cytologic proven diagnosis of a malignancy.\n4. Patient underwent a \\[18F\\]FDG PET\u002FCT.\n5. Unexplained symptoms, complaints, biochemical or imaging (scintigraphy, PET, CT, MR) findings.\n\nExclusion Criteria:\n\n1. Participant is mentally or legally incapacitated, doesn't understand the study design or is not willing or capable to undergo all study-specific procedures.\n2. Any disorder or condition, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.\n3. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial.\n4. Female who is pregnant (urinary hCG test can be performed in case of doubt), breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive (with a relatively high Pearl Index: natural methods, minipill outside postpartum period, spermicides or condoms in monotherapy or no usage of contraception when sexually active are not accepted).\n5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device when the trial designs are not considered compatible by the study team.\n6. Participation in a clinical scientific study in the last 12 months with a radiation exposure caused by the experimental procedures greater than 1 mSv.\n7. Participant has a known hypersensitivity to \\[18F\\]AlF-FAPI-74 or the used excipients.",{"count":131,"type":20},109,[133,134],"PHASE2","PHASE3","The aim of the project is to demonstrate superior detection ratio of \\[18F\\]AlF-FAPI-74 PET\u002FCT compared to \\[18F\\]FDG PET\u002FCT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of \\[18F\\]AlF-FAPI-74 PET\u002FCT in oncological patients with a clinically challenging situation.",[137,138,139,140,62,30],"Oesophageal Cancer","Gastric Cancer","Pancreatic Ductal Adenocarcinoma","FAP",[142,143,144,145,146,147,148,149,150,62,151],"Oesophagogastric adenocarcinoma","Pancreatic ductal adenocarcinoma","Clinically challenging situations","[18F]-FDG","[18F]-FAPI-74","[18F]AIF-FAPI-74","Positron emission tomography","PET","Nuclear imaging","Prospective","2025-02-06",{"date":154,"type":39},"2025-02-07",{"date":152,"type":39},{"date":157,"type":20},"2027-12",{"name":159,"class":46},"KU Leuven",3,{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":5},"100498408","phase-3-efficacy-of-esmolol-in-the-identification-of-cardiovascular-disorders-by-cirrhosis-diabetes-mellitus-and-cardiotoxic-treatments-100498408","NCT05769868","Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments","Prospective, Multicenter and Open Study to Evaluate the Efficacy of Esmolol in the Early Identification of Cardiovascular Disorders Induced by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments","CIBERbBECHO","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Absence of previous heart disease, defined as the absence of relevant cardiac structural alterations such as moderate or severe hypertrophy, alteration of segmental contraction, Moderate or severe valvular disease, intraventricular obstructive gradient, or old myocardial infarction.\n3. Existence of an at least acceptable ultrasonic window, which allows the visualization of at least 14 of the 17 segments of the LV myocardium.\n4. Sinus rhythm, with a basal heart rate greater than 50 bpm.\n5. Diabetic patients with a diagnosis of Diabetes Mellitus 2 (DM2) with or without Heart Failure with Normal Ejection Fraction (HFNEF) (n = 300) will be included. Previous diagnosis of HFNEF with clinical stability at the time of inclusion (n = 200). No previous diagnosis of HFNEF (n = 100).\n6. 200 patients with cirrhosis stratified by the following additional criteria will be included: Child-Pugh A class (n = 25); Child-Pugh B class (n = 75); Child-Pugh C class (with and without ascites n = 50 and n = 50, respectively).\n7. 300 cancer patients will be included, divided into 3 therapeutic groups: 125 patients diagnosed with Lymphoma or Sarcoma receiving chemotherapy based on anthracyclines at high doses (≥ 240 mg \u002F m2); 125 patients with Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer receiving chemotherapy regimen that includes trastuzumab without anthracyclines; 50 patients with hepatocarcinoma receiving treatment with Sorafenib.\n8. Expected survival\\> 6 months, first-diagnosis of cancer, and receiving treatment with chemotherapy that includes any of the previous schemes.\n9. A control group (n = 200) without heart disease and without any of the study conditions will be included: diabetes from any cause, cancer or active cancer treatment or some degree of liver disease.\n\nExclusion Criteria:\n\n1. Contraindication for the administration of esmolol (according to technical data sheet): Hypersensitivity to esmolol hydrochloride; Severe sinus bradycardia (HR \\\u003C50 bpm); 2nd or 3rd degree atrioventricular block without pacemaker; Cardiogenic shock, severe hypotension, or decompensated heart failure; Untreated pheochromocytoma; Acute asthmatic attack; Concomitant intravenous administration or within the first 48 hours after verapamil.\n2. Treatment with beta-blocker drugs (oral, topical or intravenous) in the last 7 days before the study.\n3. History of ventricular or supraventricular arrhythmias that prevent the safe withdrawal of antiarrhythmic or braking treatment before the administration of esmolol.\n4. History of previous high-grade atrioventricular (AV) conduction disorder in non-pacemaker patients.\n5. Severe asthma with bronchial hyperresponsiveness.\n6. Patients with acute infection.\n7. Participants in other clinical trials in the 30 days prior to the start of the study.\n8. Pregnant women, or who plan to be, and women during breastfeeding.\n9. Patients with limitation to follow the protocol for any reason.\n10. Diagnosis of Diabetes Mellitus (DM) of any type other than type 2 \\[type 1, Latent Autoimmune Diabetes in Adults (LADA), Maturity-Onset Diabetes of the Young (MODY), New Onset Diabetes After Transplant (NODAT), etc.\\]\n11. Patients in New York Heart Association (NYHA) functional class IV or with advanced heart failure.\n12. Treatment with an oral beta-blocker at the time of the examination that cannot be safely temporarily suspended 72 hours before the test.\n13. Active evidence of Hepatitis B Virus (HBV) or Hepatitis B Virus (HCV) infection.\n14. Personal history of previous cancer requiring systemic treatment (excludes skin or localized cancers treated locally surgically).\n15. Previous exposure to systemic antitumor treatment or radiotherapy on the thoracic region.",true,{"count":171,"type":20},1000,[134],"The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.",[175,176,30],"Cirrhosis","Diabetes Mellitus",[178,179,180,181,182,183,184,185],"beta blockers","echocardiography","esmolol","systolic function","cardiovascular diagnosis","biomarkers","diagnostic techniques","medical imaging","2024-09-30",{"date":188,"type":39},"2024-10-01",{"date":190,"type":39},"2023-04-18",{"date":192,"type":20},"2027-09",{"name":194,"class":195},"Consorcio Centro de Investigación Biomédica en Red (CIBER)","OTHER_GOV"]